Overview

Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease

Status:
Completed

Trial end date:
2003-06-01

Target enrollment:

Participant gender:

Summary

Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Abgenix

Collaborator:

Sangstat Medical Corporation